Johnson
However, unlike candidates, the vaccine evolved through Janssen, a subsidiary of Johnson.
“We are convinced that a singles dose can be very effective,” Johnson’s leading scientist told reporters on Wednesday.
“The singles dose may be enough for other people for a long time,” he added.
One of the benefits of a vaccine that can be given completely in a singles dose is that other people wouldn’t have to come back in a few weeks.
“A single-dose vaccine is less complicated to put into effect because it would possibly be more difficult to bring patients in for this dose at the moment,” Litjen Tan, director of strategy at the Immunization Action Coalition, told Newsweek Litjen Tan.
Multidose vaccines require more administration to make sure others are well vaccinated with the right amount of dosage.
“In order to comply, we want to put in position systems like “remember-remember” to bring this patient back to the dose of this moment,” Tan said. “And we want to make sure that the documentation of the receipt of the vaccine is well done so that we know when this patient wants to go back to the dose for a moment and provide the previous interventions. “
He added that documentation of single-dose vaccines is also included in physical fitness records.
Single-dose trials will begin and arrive with up to 60,000 participants at approximately 215 sites in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States. This is a much larger pattern than the Modern and Pfizer 30,000. 44. 000.
The experimental vaccine uses SARS-CoV-2-related adenovirus, the virus that causes COVID-19, to generate antibodies in human cells, a strategy the company used in the past to expand other vaccines, adding an opposite to Ebola.
Although no initial effects are expected for at least two months, the company expects to obtain an emergency use authorization from the US Food and Drug Administration. But it’s not the first time Until early 2021 if the vaccine is effective in the final stages of clinical trials.
The FDA has stated that a vaccine will have to prove that it protects at least 50% of participants to be considered effective.
The director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, who has worked on vaccine studies and whose firm is helping fund the trial, called the publication a “big step forward” in a call to reporters on Tuesday.
“Candidate Janssen has shown promise in the initial tests and can be of great help in controlling the pandemic if he is found to be protective after a single dose,” Fauci said.
Johnson
This is the fourth candidate vaccine in the United States to begin Phase 3 trials. Pfizer and Moderna entered the final stages in July and AstraZeneca began testing vaccines this month. the UK reported a serious adverse reaction.
The Johnson Vaccine
Without the freezing requirements, this vaccine would possibly also be less difficult to distribute because doses can be administered in local fitness clinics and pharmacies than in complex medical facilities.
Johnson
You’ve got four loose pieces left this month
To read, sign in or create an account.
Find out why nearly a quarter of a million subscribers start their day with the 5.